Study of Subcutaneous Injection of Low-dose rhGM-CSF +/- WLL in PAP.

NCT01983657 ↗

Phase 2 Unknown 40 enrolled Shanghai Pulmonary Hospital, Shanghai, China

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to establish an efficient and economic treatment scheme by evaluation of the safety and efficacy of subcutaneous injection of low-dose rhGM-CSF, or of similar injection after whole lung lavage , in patients with PAP.

Timeline

Start: 2012-01
Primary completion: 2014-06
Completion: 2014-10

Publications

Zhang F, Weng D, Su Y, Yin C, Shen L, Zhang Y, Zhou Y, Li Q, Hu Y, Li H. Therapeutic effect of subcutaneous injection of low dose recombinant human granulocyte-macrophage colony-stimulating factor on pulmonary alveolar proteinosis. Respir Res. 2020 Jan 2;21(1):1. doi: 10.1186/s12931-019-1261-1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	rhGM-CSF	Protein / enzyme biologic	1.25 ug/kg	Subcutaneous
Subject	rhGM-CSF	Protein / enzyme biologic	2.5 ug/kg	Subcutaneous

Study of Subcutaneous Injection of Low-dose rhGM-CSF +/- WLL in PAP.

Summary

Timeline

Publications

Drugs

Indications